CME 
JOBS 
OUTBREAKS 
PEER-TO-PEER 
QUIZZES & QUESTIONS 
MEDTECH The investigational agent – known as REGEN-COV (casirivimab and imdevimab) – was previously granted the Emergency Use Authorization (EUA) for the treatment of mild to moderate COVID-19. Now, those who are at high risk for progression to severe COVID-19, including hospitalization or death, have an option.
Peer-influenced content. Sources you trust. No registration required. This is HCN.
